← All trials
NCT07272135
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 28, 2018
- Primary completion
- Aug 16, 2022
- Completion date
- Aug 16, 2022
- First posted
- Dec 9, 2025
- Last posted
- Dec 9, 2025
- Enrollment
- 12
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Hammersmith Medicines ResearchLead sponsor
- Hammersmith Medicines ResearchCollaborator
- Hammersmith Medicines ResearchOfficial
Drugs studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.